In response to legal challenges by compounders, the FDA has maintained a policy that it will not enforce the requirement until it finalizes a standard MOU for states to consider
In the liraglutide group, participants, on average, lost 8.4 kilograms of body weight, with a range of 7.3 kilograms above or below that average
After years of only having injectable GLP-1s, its exciting that patients may have both a pill and an injection option
is a participant in the Living Kidney Donor Safety Study sponsored by CIHR, a volunteer board member of the American Hypertension Specialists Certification Program, co-chair of C-CHANGE, Physician Organization Chair for CHEP+, and reports honoraria and speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, CHEP+, Eisai, GSK, Janssen, KMH, Novo Nordisk, and Otsuka